Mystery disappearance delays Shaman

Shaman Pharmaceuticals Inc. announced that initiation of Phase IIb studies of Provir in respiratory syncytial virus (RSV) will be delayed about three months, after the company found that the integrity of biological samples from patients may be lost during storage.

In SHMN's Phase IIa trial, 30 children were treated to evaluate the tolerance and safety of Provir, and to assess the degree of absorption and metabolism by determining the plasma and urine levels of drug and of a metabolite...